Pfizer Inc. has promised investors that it will grow its current inline business (excluding foreign exchange and COVID-19 revenues) at a compound annual growth rate of 6% or higher through 2025 and that it can continue to grow through 2030 despite what is expected to be heavy headwinds from losses of exclusivity (LOEs) beginning in 2026.
Pfizer Lays Out A Growth Plan To Offset $17bn In Coming Exclusivity Losses
Management presented a strategy for establishing new blockbuster brands in migraine, RSV, inflammatory bowel disease, cancer and diabetes/obesity during an investor day.
